Connect with us

Biotech

Novavax, Moderna, and BioNTech Vaccine Sales: Where Are They Now?

As vaccine sales for Novavax, Moderna, and BioNTech shift in line with a changing Covid-19 situation, the results are being felt in the stock markets. Here we look at the latest reports from Novavax, Moderna, and BioNTech, all of which have just posted record H1 results. However, investors are not convinced, with a closer look at Q2 results revealing a sharp drop-off in vaccine sales.

Published

on

With reporting season rolling around, it’s time we look at how pharmaceutical companies are shaping up in the face of a changing Covid-19 situation. Here’s a quick rundown of the reports from Novavax, Moderna, and BioNTech.

BioNTech Increases Its Profit by 37.2%, but Falls 10% On the Stock Market

German laboratory BioNTech improved its accounts in the first half of this year, posting a net profit of 5.37 billion euros, 37.2% more than in the same period last year. And sales in the first six months were 9,571.1 million euros, 30% more. But the result failed to seduce the stock market. 

Part of the reason for its failure to impress markets could be that, in the second quarter of the year, BioNTech reduced its profit by 42.3% compared to the same period of the previous year, reaching 2,3 billion euros. For its part, turnover fell by 39.8%, to 3.2 billion euros.

The German laboratory, which is responsible for one of the Covid-19 vaccines in partnership with the American Pfizer, forecasts sales of between 13 billion euros and 17 billion euros in 2022 for this drug. However, the market has not taken the company’s medium-term forecasts for granted. Today, BioNTech’s share value has plummeted 9.3% to $164.

“In the first half of 2022, we achieved important milestones as we further strengthened our leadership in COVID-19 vaccines and expanded our extensive portfolio, and accelerated its maturation,” said Ugur Sahin, CEO, and co-founder of BioNTech.

Moderna Increases Its Profit by 46% Boosted by its Covid-19 Vaccine

Moderna remains unstoppable thanks to its vaccine against Covid-19. In the first half, the US biotech increased its profit by 46% compared to the same period in 2021 and earned $5.85 billion, according to the company’s accounts.

Between January and June of this year, the company invoiced $10.8 billion, representing an increase of 70.9%. In addition, Moderna hopes to enter 21,000 million dollars in 2022, thanks to the agreements signed to sell its vaccine.

SEE ALSO  The retirement of defined benefit pensions

These contracts include the announced agreement with the United States Government for seventy million Covid-19 vaccine doses, and an adjustment for the doses that remain unassigned through the Covax mechanism due to lack of demand.

Moderna forecasts that, when it comes to second half sales of its Covid-19 vaccine, sales will be higher “in the fourth quarter than in the third, driven by the updated vaccine approval schedule and a corresponding increase in new product manufacturing.”

At the end of the second quarter, the biotechnology company obtained a profit of $2.2 billion, 21% less than the result recorded in the same period of 2021 . Sales between April and June totaled $4.75 billion, 9% more.

Novavax Cuts Its Annual Covid-19 Vaccine Sales Forecast in Half Due to Low Demand

Novavax has cut its billing forecasts for 2022 in half, to $2 billion. This modification is due to falling US coronavirus vaccine sales, as reported by the company in a statement.

Last month, the company’s shot was licensed for use among adults in the United States. However, according to the latest government data, only 7,000 doses of this vaccine have been administered in the country so far.

“I think we are late to the vaccination market in the United States,” explained the company’s CEO, Stanley Erck. This modification comes in a context where buyers, including Covax and the European Union (EU), are asking manufacturers to delay or reduce deliveries of injections since supply exceeds demand.

At the end of February, the biotech company began sending the first doses of Nuvavoxid, its vaccine against Covid-19, also known as NVX-CoV2373, to EU member states.

Novavax and the European Commission (EC) have an advance purchase agreement for up to 100 million doses of Nuvaxovid with the option of an additional 100 million doses (up to 200 million doses in total).

SEE ALSO  Moneyveo takes gold in the PaySpace Magazine Awards 2019

This was the fifth vaccine to receive the go-ahead from European regulators, after those promoted by BioNTech and Pfizer, Moderna, AstraZeneca, and Janssen. Valneva doses were added in June. In the case of Nuvaxovid, it is the first approved vaccine that uses a different platform since it is based on recombinant proteins.

__

(Featured image by Cottonbro via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce (sources: 1, 2, and 3), a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.